The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant intralesional Daromun (L19IL2/L19TNF) improved recurrence-free survival in fully resectable stage III melanoma, with hazard ratio 0.59 (P = .005) at 21 months.
- Why it matters: Stage III melanoma that is fully resectable still carries high relapse risk, and prior evidence needed longer follow-up plus confirmation across related endpoints and safety.
- What they did: In the phase III PIVOTAL trial (NCT02938299), 256 European Union patients received daromun followed by surgery versus up-front surgery, with updated efficacy and safety analyzed at median follow-up 36.8 months.
- The result: Updated analyses confirmed statistically and clinically meaningful gains in RFS and distant metastasis-free survival, and post hoc event-free survival consistency supported robustness without new safety signals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.